By Robb M. Stewart Tharimmune's shares were under pressure Thursday despite the company's lead clinical asset receiving what it said was positive feedback from the Food and Drug Administration on...
Tharimmune Shares Drop Premarket Following FDA Feedback on Plan for Lead Clinical Asset